The European Commission (EC) is reviewing AbbVie’s [NYSE:ABBV] proposed acquisition of Botox producer Allergan [NYSE:AGN]. The merging parties have already pledged to divest such products as brazikumab, a drug under development for ulcerative colitis and Crohn’s disease, and Zenpep (pancrelipase), which treats a pancreatic disorder, but the EC may want more changes if it is to approve the deal. Dealreporter’s Pablo Mayo Cerqueiro and Mergermarket’s Mintoi Chessa-Florea joined us to discuss how the EC’s review is likely to go.
Danish pharmaceutical company Lundbeck [CPH: LUN] is poised for a run of M&A to replenish its drug pipeline. We caught up with our Nordics reporter, Karoliina Liimatainen, who spoke recently with the company's chief executive, Deborah Dunsire, and has more on the company's plans for growth.
A year on from the last time we sat down with Anya Cummins, Partner and Head of M&A at Deloitte we wanted to see if there is any more certainty around Brexit since Article 50 was triggered. We were also keen to find out what the deal drivers are for Irish M&A and PE investments in the next 12 months.
A panel of bankers and corporates sat down at the Mergermaket Germany Forum to discuss the outlook for their sectors and companies and the M&A drivers that will play in delivering growth. Here's what they said...